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Bioactive and luminescent indole and isatin based gold(I) 
derivatives
Vanesa Fernández-Moreira,*[a] Cynthia Val-Campillo,[a] Isaura Ospino, [b] Raquel P. Herrera,[c] Isabel 
Marzo,[d] Antonio Laguna[a] and M. Concepción Gimeno*[a]
A series of luminescent monometallic [AuL(PPh3)] (1-3) and bimetallic [Au2(µ-dppe)L2] (4, 6, 8) and [Au2(µ-dppp)L2] (5, 7, 9) 
complexes, where L is either 4-cyano-indole, isatin, or 5,7-dimethyl-isatin, and dppe and dppp are 1,2-
bis(diphenylphosphino)ethane and 1,3-bis(diphenylphosphino)propane, respectively, have been synthesised. X-ray 
diffraction confirmed the tendency to establish aurophillic interations for those complexes containing dppe. Luminescent 
studies and theoretical calculations revealed a different origin for both families, i.e. indole and isatin species. Thus, indole 
derivatives presented a ligand-to-ligand-charge-transfer transition (LLCT) from the indole to the PPh3 fragment, whereas 
for the isatin derivatives an intraligand–charge-transfer transition (ILCT) within the isatin fragment is proposed. In both 
cases the gold centre slightly implicated as a ligand-to-metal-charge transfer transition (LMCT) (from the indole/isatin to 
Au(I)). Cell antiproliferative assays in lung cancer cells (A549), leukemia Jurkat-pLVTHM and Jurkat-shBak cells (cisplatin 
sensitive and resistant respectively) showed excellent cytotoxic values (10.11 - 0.28 μM), resulting the leukemia cells the 
most sensitive and the bimetallic species the most active agents. Preliminary studies associated the cytotoxicity to a 
combination of diferent factors, being the metallic fragment the main responsible. Remarkably, these complexes are able 
to inhibit the cellular growth of cisplatin resistant Jurkat-shBak cells highlighting their promising future as an alternative 
anticancer agent.
Introduction
Indole has become one of the most privileged structural motif 
in drug discovery and it exists in a great number of active 
natural and non-natural products.1 Its interesting properties 
cover diverse research areas such as pharmaceuticals, 
fragrances, agrochemicals, pigments, and material science 
being many of these compounds already drugs on market or 
compounds in clinical trials (Figure 1).2 The importance 
attained by the indole derivatives and their broad scope of 
applications justifies its appellation as the “The Lord of the 
Rings” of the aromatic compounds.3 Therefore, the design of 
new indole structures with appealing properties is still an 
active challenge and the goal of considerable efforts by many 
research groups.4
Other related structure is the isatin skeleton which has gained 
much attention from organic and medicinal chemists, since 
this motif also constitutes the structural core of a great 
number of natural products as well as several other drug 
candidates (Figure 1).5 Together with all this broad spectrum 
of biological properties,6 indole and isatin derivatives also play 
an important role in bioluminescence. Therefore, their light 
emission properties have become subject of research, 
although less explored than their bioactivity but sometimes 
associated to this.7 On the bases of our continuous search on 
the development of new biologically active gold complexes8 
and their combination with luminescent fragments9 in order to 
to be used as emissive tags, the exploration of new indole and 
isatin gold based derivatives could be an excellent approach 
for delivering novel bioactive metallodrugs. 
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Fig 1. Selection of indole and isatin derivatives biologically active.
In spite of the increasing number of bioactive indole 
compounds found in the literature, it is noticeable that there 
are scarce examples of indole or isatin derivatives bonded to 
gold10 and only a couple of them dealing with the cytotoxic 
activity.10c,10d Recent investigations dealing with gold 
complexes containing azaindoles reveal their great potential as 
an alternative to cisplatin for the treatment of ovarian 
carcinoma, in particular in A24780 carcinoma cell.11 Similarly, 
other gold complexes containing in their structure fussed 
heterocyclic N-donor ligands, such as purine,12 adenine13 or 
xanthine,14 i.e. similar structures to those of indole or isatin, 
expose their incredible prospective as partners of bioactive 
gold(I) species. For that reason, we intend to evaluate the 
antitumor activity of a variety of indole and isatin based gold 
complexes, as well as their luminescence for their plausible 
use in cell imaging. The antitumor properties of gold 
derivatives with nitrogen-based ligands have been more 
extensively studied for gold(III).15 However, not many 
examples have been described for gold(I), which is mainly 
dominated by sulfur, carbon or phosphine type ligands.16 This 
is the first study of the antitumour properties of indole and 
isatin based gold derivatives. Therefore, this study would 
contribute to widen the knowledge regarding the bioactivity of 
gold(I) complexes containing N-donor ligands.
Results and Discussion
Three representative structures were selected for this 
investigation; 4-cyanoindole L1, isatin L2 and 5,7-
dimethylindoline-2,3-dione L3. Thus, L1 bearing a nitrile group 
provides an easily transformable site to different 
functionalities, among others, to acid or aldehyde groups 
which could be useful intermediates for different structures.17 
The isatin L2 is the structural core of the many bioactive 
compounds,5 and the L3 derivative is also present in diverse 
important biological structures.18
Synthetic procedure and characterization
Monometallic gold(I) complexes (1-3) were synthesised by 
reaction of the corresponding indole or isatin derivative L1-L3, 
Figure 2, with [AuCl(PPh3)] in presence of Cs2CO3 to assist the 
amine deprotonation. The same synthetic procedure was 
followed for the synthesis of bimetallic complexes (4-9), using 
either [Au2Cl2(µ-dppe)] or [Au2Cl2(µ-dppp)] instead of 
[AuCl(PPh3)], being dppe: 1,2-bis(diphenylphosphino)ethane 
and dppp: 1,3-bis(diphenylphosphino)propane. Spectroscopic 
characterisation of each complex was performed by IR, 1H, 
31P{1H} and 13C{1H} NMR spectroscopy and the most relevant 
data are collected in Table 1. Infrared spectroscopy showed in 
all cases the disappearance of the (N–H) stretching bands at 
ca. 3320 cm-1 for the 4-cyanoindole derivatives and 3188 cm-1 
in the case of isatin derivatives, indicating the deprotonation 
of the amine groups and further coordination to the gold 
fragment. 
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Fig 2. Representation of L1-L3 and their corresponding monometallic 1-3 and bimetallic 
4-9 gold(I) complexes. Numbering for the NMR assignments is depicted for L1.
Table 1. Selected IR frequencies and 31P, 1H and 13C NMR chemical shifts for L1-
L3 and complexes 1-9. IR spectra were measured in solid state and NMR spectra 
recorded in CDCl3. Experimental data for complex 2 reported somewhere else.19
IR / (cm-1) 31P{1H} 
NMR / 
(ppm)
1H NMR / 
(ppm)
13C NMR / 
(ppm)
L1 2230, 2014a - 6.78c 138.6h
L2 1745, 1724, 1613b - 6.92d 150.7g
L3 1729, 1613b - 7.20e 147.1
1 2213a 31.3 6.76-6.74c 144.6f
3 1719, 1679, 1615b 32.1 7.13e 157.6f
4 2208a 30.4 6.75c -
5 2208a 23.4 6.68c 144.5f
6 1726, 1682, 1601b 26.6 6.76d 160.7f
7 1726, 1682, 1602b 25.4 6.80-6.70d 161.7f
8 1730, 1669, 1616b 27.4 6.76e 156.9f
9 1722, 1678, 1615b 25.0 6.81e 157.2f
 a (CN), b (CO), c δ(CH(3)), d δ(CH(7)), e δ(CH(4)), f δ(C(7a)), g δ(C(7a)) in DMSO-d6, 
h δ(C(7a)) in CDCl3. 
In addition, the characteristic strong (C≡N) stretching band of 
4-cyanoindole that appears at 2230(sh) and 2214 cm-1 is shifted 
to 2213 cm-1 (compound 1) and 2208 cm-1 (complexes 4 and 5) 
upon complexation, presenting also a considerably intensity 
decrease. Moreover, the IR spectrum of L2 and L3 presented 
strong absorptions in the carbonyl region at c.a. 1745, 1724 
and 1613 cm-1 that are shifted to lower frequencies when the 
coordination reaction takes place, i.e. around 1726, 1682 and 
1601 cm-1.10b Further spectroscopic data provided by 31P NMR 
spectra measured at room temperature exhibited only one 
resonance. The typical chemical shift for a PPh3P-Au-N 
environment was observed in the range 30-32 ppm and at 
highfield those corresponding to the bimetallic species.20 In 
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addition, dppp derivatives, i.e. species 5, 7 and 9, displayed the 
lowest phosphorous chemical shift which can be attributed to 
small variations in the dihedral or bond angles promoted by 
the different number of methylene spacers among the two 
phosphorous atoms.21 Moreover, chemical shifts observed in 
13C{1H} NMR and 1H NMR spectroscopy also corroborated the 
success of the complexation reaction. Thus, complexes 1–8 
showed a deshielding effect of the C(7a) as a result of the 
coordination of L1, L2 and L3 to the gold fragments. 
Specifically, the C(7a) chemical shift is observed at ca. 144, 157 
and 161 ppm for the different gold families respectively. 
Moreover, phenyl carbon atoms are well defined in the 13C 
NMR, exhibiting magnetically inequivalent atoms for the dppe 
derivatives. As a result, complexes 4, 6 and 8 presented 
pseudo-triplets (“t”) for meta and ortho carbons, i.e. doublets 
of doublets with Jpc = Jpc’ = 6-7 Hz, similar to those seen in 
analogous complexes.20 This magnetic inequivalence is not 
unexpected due to the symmetry of the molecule.22 In 
addition, the disappearance of the signal belonging to N–H 
protons together with the chemical shifts presented by the 
most characteristic protons of L1 (CH(3)), L2 ((CH(7)), and L3 
(CH(4)) evidences the successful formation of the desired gold 
complexes 1-9. In addition, stability of the complexes was 
tested for selected species (compound 6) in a highly 
coordinative solvent, DMSO-d6, by 1H and 31P-NMR 
spectroscopy, see Figure S1. The experiment showed that 
complex 6 was able to remain unaltered for at least 24h under 
those conditions. Electrospray ionisation mass spectroscopy 
(ESI-MS) was used to analyse the fragmentation of the 
molecules. Unfortunately, molecular ions were only observed 
for complexes 1, 3 and 4. Instead, all other compounds 
displayed the typical fragmentation pattern where one of the 
ligands (L1, L2 or L3) is lost. The stability of the complexes in 
DMSO solution is comprised by the presence of PBS buffer 
after 6 hours, but it is not up to 24h when a clear The stability 
of complexes Interestingly, crystals of 6, 7 and 8 suitable for X-
ray analysis were obtained by slow diffusion of either ether or 
hexane into a solution of acetone or dichloromethane.
X-ray Crystallography
Single crystals suitable for X-ray diffraction analysis of 
complexes 6, 7, 8 were obtained by slow diffusion of either 
ether or hexane into a solution of the complex in 
dichloromethane (DCM) or acetone, (see Figures 3 and 4). 
They presented a tetragonal, triclinic and monoclinic crystal 
system, respectively, and the asymmetric unit is formed by 
half molecule of 6, one of 7 and two independent molecules of 
8, Table S1. Only compound 6 bears crystallisation solvent 
molecules trapped in their crystalline structure (DCM and 
H2O). All of them presented the typical bond lengths and 
distorted linear disposition around the metal centre. Thus, Au-
P distances range from 2.229(3) to 2.241(3) Å, Au-N distances 
are between 2.047(8) and 2.057(4) Å and N-Au-P angles lie 
among 170.5(2) and 179.25(13)°.10a,19,23 A summary of most 
significant bond distances and angles is collected in Figure 3 
and 4. Aurophilic interactions were observed in the case of the 
bimetallic complexes 6 and 8.24 Possibly, the presence of the 
dppe as the bridging ligand instead of dppp is allowing these 
interactions take place. Therefore, folding of dppe renders a c-
shape disposition where coordinated gold atoms are within 
the range of stablishing intramolecular gold interactions and 
the subsequent structure stabilization. Torsion angles of the 
system P-C-C-P are 33.5(3)° (6), 75.1(9)° (8A) and 104.6(7)° 
(8B). Instead, dppp does not offer such possibility and its 
methylene chain prefers to adopt an extended disposition, 
(see Figure 3). Specifically, the Au-Au distance observed for 
molecules 6 and 8A and 8B are 3.0141(6) and 3.0058(5) and 
3.1136(6) Å respectively values in the range of aurophilic 
interactions.24 Moreover, offset- π-π interactions between the 
parallel fused phenyl rings of the isatin units are also seen for 
complexes 6 and 8A and 8B. Centroid-centroid distances are 
3.660, 3.689, 3.600 Å, respectively, and the angle between the 
perpendicular line to the phenyl and the centroid-centroid 
vector ranges from 19.01 to 22.30°, see Figure S2-S4.25 
In the particular case of compound 8, short contact 
interactions among the two independent molecules of the 
asymmetric unit are also revealed. Hence, the specific 
intermolecular interactions are those stablished between 
H95···C6 (2.285 Å), H95···H18B (2.373 Å), O5···H17A (2.506 Å) 
and H112···C25 (2.796 Å), Figure S5. None hydrogen bond 
interaction is observed. Alternatively, the linearity of 
compound 7, due to the bridging dppp ligand, causes that the 
gold atoms are located in the furthermost position and no 
additional intramolecular interactions between the isatin unit 
and/or the phenyl rings are found. 
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Fig 3. Depiction of the molecular structure of complexes 6 and 7 and a summary 
of their most relevant bond length (Å) and angles (°). Complex 6: Au1-P1 
2.2401(16), Au1-N1 2.050(7), Au1-Au1 3.0141(6); N1-Au1-P1 174.19(15). 
Complex 7: Au1-P1 2.2362(13), Au1-N1 2.057(4); N1-Au1-P1 179.25(13), Au2-P2 
2.2403(12), Au2-N2 2.086(7); N2-Au2-P2 172.3(3).
Fig 4. X-ray representation of the molecular structure of complex 8 and summary of 
their most relevant bond lengths (Å) and angles (°). Molecule 8A: Au1-P1 2.239(2), Au1-
N1 2.065(7), Au1-Au2 3.0058(5), Au2-P2 2.241(3), Au2-N2 2.047(8)¸ N1-Au1-P1 
170.5(2), N2-Au2-P2 175.1(2). Molecule 8B: Au3-P3 2.237(2), Au3-N3 2.048(8), Au3-
Au4 3.1136(6), Au4-P4 2.229(3), Au4-N4 2.056(8); N3-Au3-P3 173.0(3), N4-Au4-P4: 
176.2(2).
Photophysical properties
UV-visible absorption spectra of complexes 1-9 were recorded 
in a DCM solution at 298 K and the most relevant data are 
summarised in Table 2. The absorption spectra of complexes 1-
9 showed an intense absorption band at ca. 235 nm that can 
be attributed to ligand centred transitions, π→π* among L1, 
L2, L3 and also among the phenyl units. Moreover, the less 
intense bands at lower energies are thought to be n→π* 
transitions within the cyano or carbonyl group and the N-C of 
the heterocycle, see Figure S6.26 Emission and excitation 
spectra were also recorded for 1-9 in DCM solution as well as 
for L1, L2 and L3 for comparison purposes. The emission 
maxima of the ligands differ completely upon their chemical 
nature (Figure 5). Thus, L1 presented an emission maximum at 
365 nm and L2 and L3 at 524 and 554 nm, respectively. For 
both families, these emissions can be assigned to IL transitions, 
where their different electron density plays an important role 
on the HOMO and LUMO energy levels.27 In contrast, 
complexes 1-9 presented a similar behaviour, featureless 
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emission bands with an emission maximum between 371 and 
429 nm. Specifically, complexes 1, 4 and 5 displayed an 
emission band centred at c.a. 407 nm implying a shift to lower 
energy compared to their precursor L1. In contrast, complexes 
2, 3 presented an emission at 383 and 371 nm and their 
analogous bimetallic species at 398 nm and at c.a. 424 nm 
exhibiting a considerable shift to higher energies from their 
correspondent uncoordinated ligands L2 and L3. The fact that 
the emission maxima of 1-9 are similar, with variation of only 
58 nm, contrasting with that observed for L1, L2 and L3 of 189 
nm, suggests that the gold-phosphine fragment must have 
some sort of implication in the electronic transition. Taking 
into account the emission values seen for 1-9, all of them close 
to 400 nm, an emission derived from a mixture of LLCT and 
LMCT transition could be proposed, where possibly the LLCT 
transition has a higher contribution because of such high 
energy emission value. Moreover, the low lifetime displayed 
by all the complexes (0.156-0.721 µs) suggest that the 
participation of the metal centre in the transition, if there is 
one, it would be small. These lifetime values are typical from a 
fluorescent transition which is in concordance with the small 
Stokes shift seen, from 35 to 70 nm, see Figure S7.28 Moreover, 
it is also worth noticing that the aurophilic interactions seen in 
solid state for complexes 6 and 8 are not maintained in 
solution, as none emission, ie. MMCT transition, at lower 
energy (c.a. 600 nm) is seen that might suggest otherwise. As a 
result, the photophysical properties of the mono- and 
bimetallic species are alike.
Table 2. Absorption, emission, excitation and lifetimes of complexes 1-9 measured in 
DCM at 298K. (λem/nm (λexc / nm): L1, 365 (337); L2, 524 (337); L3, 554 (353).
UV-vis (×104 Ɛ/dm3 mol_1 cm_1) λem/nm (λexc / nm) ζ / µs
1 231(67000), 276(19800), 
305(16200), 341(10800)
407 (337) 0.174
2 245(38400), 260(26200) 383 (337) 0.178
3 245(30400), 270(14600), 
300(3000)
371 (331) -
4 230(132400), 275(37000), 
303(25000), 350(5000)
407 (373) 0.156
5 232(94200), 273(29800), 
304(23400), 341(1000)
407 (376) 0.197 
6 230(106000), 249(58200), 
259(42400), 276(30000), 
305(11800)
398 (338) 0.721
7 242(66600), 276(15400) 398 (342) 0.638
8 241(69200), 255(58400), 
268(33000), 305(13200), 
442(2400)
429 (359) 0.211
9 237(127600), 255(110600), 
311(21000), 451(4000)
424(355) 0.198
Fig 5. Emission spectra of L1-L3 and complexes 1-9 measured in DCM solution.
Theoretical calculations
In order to gain insight into the different photophysical 
behaviour observed for L1-L3 and 1-9, we carried out DFT and 
TD-DFT calculations on representative systems, specifically L1, 
L2, 1 (L1Au) and 2 (L2Au). We analised their electronic 
structure and electronic transitions. Each structure were fully 
optimised in the ground state at the DFT level using the 
PBE1PBE functional. The solvent effects were performed using 
the IEFPCM approach considering the noncoordinant solvent, 
dichloromethane. Frequency calculations were also performed 
and their positive value confirms the stability of the optimised 
geometry. Moreover, the optimised parameters of the 
selected species are in agreement with the experimental data 
of analogous systems (See Figure S8 and Table S2 of 
Supporting Information).29
The energy gap (ΔEH–L) is the energy difference between the 
highest occupied molecular orbital (HOMO) and lowest 
unoccupied molecular orbital (LUMO) and it is largely 
responsible for the chemical and spectroscopic properties of 
the molecules.30 Theoretically calculated frontier molecular 
orbitals in the ground state including HOMO–LUMO energy 
levels and energy gap are illustrated in Figure 6. L2 has a 
smaller energy gap than L1. Hence the eventual charge 
transfer occurs easier for isatin species, L2, which correlates 
with the emission maxima seen experimentally (524 nm for L2 
and 365 nm for L1). This band has been reported as an intra-
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ligand charge transfer transition (ILCT). The distributions of 
electron density of HOMO and LUMO orbitals of L1 and L2 
predominantly moves in the fragment -NHCRCR- (R= H or O), 
indicating an increase in the charge transfer character of the 
transition on going from L1 to L2.
The Au(I) complexes reported in this study are luminescent, 
they emit in the blue region of the spectrum. The presence of 
low-energy emission and absorption bands in the electronic 
spectra, support the assignment of the luminescence to a 
LMCT but it is not clear the role of the metal. To gain insight 
into the nature of the orbitals of the complexes and the 
relative trends in orbital energies according to their respective 
ligands, molecular orbital calculations were carried out for 
complexes 1 (L1Au) and 2 (L2Au). When the metal fragment is 
coordinated to L1 and L2, a decrease in the HOMO-LUMO gap 
energy was observed. This could be due to a strong energy 
destabilisation of the HOMO and LUMO orbitals in all cases 
(L1Au and L2Au). For complex 1 the emission band is shifted to 
lower energy compared to their precursor L1. In contrast, 
complex 2 presented a considerable shift to higher energies 
from their correspondent ligand L2. These shifts in energy of 
the different complexes indicate the participation of orbitals of 
the different ligands. The calculated HOMO and LUMO of 1 
and 2 are shown in Figure 6. In the case of 1, the HOMO 
consists mainly of indole ligand orbitals (97%) whereas the 
LUMO is formed by a contribution from the PPh3 ligand (97%). 
Both HOMO and LUMO have a slightly participation of the gold 
metal (3%). Therefore, in the eventual transition an alternative 
assignment must be considered, an indole-ligand to PPh3-
ligand charge transfer (LLCT) with a small contribution of the 
gold metal.
Fig 6. Frontier molecular orbitals and ΔEH–L for L1, L2, L1Au and L2Au. H and L 
denote the highest occupied and lowest unoccupied molecular orbitals, 
respectively.
In the case of complex 2, its HOMO is mainly located in the 
orbitals of the isatin ligand (93%) and gold metal (7%), whereas 
the LUMO has high participation of isatin ligand orbitals (98%). 
In contrast with complex 1, there is no contribution from the 
PPh3 ligand. Consequently, the emissive behaviour of complex 
2 could be assigned to ligand to metal charge transfer (LMCT) 
mixed with intraligand charge transfer (IL-CT) (isatin centred) 
with some contribution from the metal.
Biological activity.
The antiproliferative properties of complexes 1-9 were 
assessed in several cancer cell lines, i.e. lung A549 cells and 
leukemia Jurkat-pLVTHM and Jurkat-shBak cells, by monitoring 
their ability to inhibit cell growth using the MTT assay. Jurkat-
pLVTHM and Jurkat-shBak cells are known to be cisplatin 
sensitive and resistant cells, respectively.31 Therefore, the 
results here presented will provide additional information 
regarding the cytotoxicity of the complexes 1-9 in cancer cells 
where the cisplatin has no use, with the expectation of 
presenting them as an alternative treatment. The results of 
these tests are summarised in Table 3. There is a clear trend in 
the cytotoxic activity of the different complexes in the three 
cell lines. Bimetallic species 4-9 are able to inhibit much more 
the proliferative activity than the monometallic species 1-3, 
reaching IC50 values up to 19 times smaller, as for instance in 
the case of IC50(3) = 9.09 ± 1.19 vs IC50(8) = 0.48 ± 0.05 μM in 
Jurkat-shBak cells. The same trend have been observed for the 
indole family in HeLa cells, see caption of table 3. It is 
important to point out the role of gold coordination for 
achieving certain antiproliferative effect as none of the ligands, 
L1-L3, presented any cytotoxicity in A549 cells at the measured 
concentrations by themselves (IC50 > 100 μM). In addition to 
them, [Au(indole)PPh3] was also tested to elucidate any 
possible influence of indole or isatin substituents within the 
cytotoxic activity. However, the similar IC50 values found for 1-
3 and [Au(indole)PPh3] in the three cell lines revealed a low 
influence of the substituents on the antiproliferitive activity. It 
is crucial to notice that diphosphine derivatives such as dppe 
have been already proved to bear cytotoxic by itself.32 
Therefore, the higher antiproliferative effect exhibited by the 
bimetallic species in comparison with that of the monometallic 
could be assigned to a cooperative effect between the 
presence of two gold centres and the diphosphine fragment. 
To support this idea, the antiproliferative activity of dppe and 
dppp was measured in Jurkat-pLTVHM cells giving IC50 values 
close to 50 μM. Such high IC50 values point towards the metal 
centre as the main responsible for cytotoxicity, possibly 
targeting the thioredoxin reductase (TrxR) by comparison with 
multiple examples on gold complexes reported in the 
literature.33 Additionally, both leukemia cell lines were 
sensitive to the action of 1–9, contrasting with the non-
antiproliferative character of cisplatin in Jurkat-shBak cells,34 
and proposing these gold species as a new source of an 
alternative treatment to cisplatin. Alternatively, cytotoxicity of 
selected complexes (1, 2, 4 – 6) was examined in a non-
cancerous cell line, MEF cells (mouse embryo fibroblast), see 
table 3. Despite that this preliminary analysis revealed also a 
high antiproliferative character, their selectivity towards 
cancer cells cannot be ruled out as mouse embryo fibroblast 
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are not comparable to human healthy cells. Additionally, 
inhibition of the thioredoxin assay was performed for complex 
6. Specifically, A549 cells were treated with 6 (DMSO) for 4 h. 
Then, total protein extracts were prepared and used for the 
determination of thioredoxin activity. Subsequently, the 
artificial substrate 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) 
was added. DTNB would rapidly evolve to two molecules of 2-
nitro-5-thiobenzoaye anion (TNB) if thioredoxin redutase is in 
the presence of NADPH. Thus, the reduction of DTNB to TNB 
affords a yellow colour that can be detected at 412 nm by UV-
absorption.35 The evolution of the TNB formation was 
recorded for 5 min and compared with that of a control assay. 
As a result of the comparison, no inhibition of the thioredoxin 
was observed, see Figure 7. This result was further 
corroborated by a preliminary analysis on the production of 
reactive oxygen species (ROS) in colorectal adenocarcinoma 
cells (CACO cells). Once again, incubation of complex 6 with 
CACO cells did not promote the production of ROS postulating 
the existence of a different biological target than that of 
thioredoxin.
Finally, stability of the complexes was analysed for selected 
species, complexes 2 and 6 in mixtures of PBS:DMSO and 
DEMEM:DMSO (0.05%) by UV-absorption spectroscopy, see 
figure S9. In both cases the complexes remained intact up to 6 
h, after that a new absorption band was observed over 350 nm 
as a result of the formation of new species. 
Table 3. IC50 values of complexes 1-9 measured by an MTT assay after 24h 
incubation in A549, Jurkat-pLTVHM, Jurkat-shBak and MEF cells.
A549 Jurkat-pLTVHM Jurkat-shBak MEF
1 6.50 ± 2.30 7.61 ± 1.57 4.41 ± 0.93 0.22 ± 0.01
2 10.11 ± 7.61 2.89 ± 1.07 4.45 ± 1.80 1.80±0.28
3 6.89 ± 1.25 6.34 ± 0.69 9.09 ± 1.19 -
4 1.71 ± 0.45 0.67 ± 0.02 2.20 ± 0.29 1.80 ± 0.21
5 1.65 ± 0.26 1.05 ± 0.02 1.80 ± 0.32 0.38 ± 0.005
6 1.00 ± 0.22 1.69 ± 0.12 0.85 ± 0.02 2.91 ± 0.22
7 1.22 ± 0.12 0.57 ± 0.004 0.28 ± 0.004 -
8 1.09 ± 0.07 0.16 ± 0.05 0.48 ± 0.05 -
9 1.25 ± 0.22 1.06 ± 0.81 1.67 ± 0.59 -
10 8.32 ± 1.49 7.34 ± 2.73 3.91 ± 0.55 -
10 = [AuPPh3(indole)]. IC50 (L1, L2, L3) >100μM in A549 cells, IC50 (dppe, dppp) 
>50 μM in Jurkat-pLTVHM cells, IC50 (1, 4, 5 and [Au(indole)PPh3]) = 11.7 ± 3.12, 
2.81 ± 0.54, 2.58 ± 0.63 8.95 ± 2.08 respectively in HeLa cells.
Fig 7. Inhibition of thioredoxin assay for complex 6. Representation of the evolution of 
absorbance intensity of TNB during 5 minutes.
Experimental Section
Mass spectra were recorded on a BRUKER ESQUIRE 3000 PLUS, 
with the electrospray (ESI) technique. 1H, 13C{H} and 31P NMR, 
including 2D experiments, were recorded at room 
temperature on a BRUKER AVANCE 400 spectrometer (1H, 400 
MHz, 13C, 100.6 MHz, 31P, 162 MHz) with chemical shifts (δ, 
ppm) reported relative to the solvent peaks of the deuterated 
solvent. Infrared spectra were recorded in the range 4000–250 
cm-1 on a Perkin-Elmer Spectrum 100 FTIR spectrometer. 
Room temperature steady-state emission and excitation 
spectra were recorded with a Jobin-Yvon-Horiba fluorolog FL3-
11 spectrometer fitted with a JY TBX picosecond detection 
module. UV/vis spectra were recorded with a 1 cm quartz cells 
on an Evolution 600 spectrophotometer.
Theoretical calculations.
For all calculations, with Gaussian 09,36 we have used the 
PBEPBE density functional37 and the solvent effects were 
introduced through the IEFPCM polarisable continuum 
model.38 The pseudopotentials from Stuttgart,39 and the 
corresponding basis sets augmented with two f polarization 
functions40 were employed for the metal Au and def2-SVP 
basis set for all atoms.41 Vibrational frequencies were 
calculated at the same theoretical level to confirm that each 
configuration was a minimum on the potential energy surface. 
The Supporting Information contains Cartesian coordinates for 
all optimised structures. 
Crystal structure determinations
Crystals were mounted in inert oil on glass fibres and 
transferred to the cold gas stream of an Xcalibur Oxford 
Diffraction diffractometer equipped with a low-temperature 
attachment. Data were collected using monochromated MoK 
radiation ( = 0.71073 Å). Scan type . Absorption corrections 
based on multiple scans were applied using spherical 
harmonics implemented in SCALE3 ABSPACK scaling 
algorithm.42 The structures were solved with the ShelXS 
structure solution program using direct methods and by using 
Olex2 as the graphical interface.43  The model was refined 
using the program SHELXL.44 All non-hydrogen atoms were 
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refined anisotropically. Further details on the crystal 
refinements are collected in Table S1. CCDC reference 
numbers 1818688 (6), 1818689 (7) and 1818690 (8).
Cytotoxicity assay
The MTT assay was used to determine cell viability as an 
indicator for cells sensitivity to the complexes. Exponentially 
growing cells A549, HeLa, Jurkat-pLVTHM,  Jurkat-shBak and 
MEF fibroblast were seeded at a density of approximately 104 
cells (A549) or 3x104 cells (Jurkat-pLVTHM and Jurkat-shBak) 
per well in 96-well flat-bottomed microplates and allowed to 
attach (A549) or grow for 24 h prior to addition of compounds. 
The complexes were dissolved in DMSO and added to cells in 
concentrations ranging from 0.1 to 100 µM in quadruplicate. 
Cells were incubated with the compounds for 24 h at 37 °C. 
Ten microliters of MTT (5 mg ml-1) were added to each well 
and plates were incubated for 2 h at 37 °C. Then, media was 
eliminated and DMSO (100 µl per well) was added to dissolve 
the formazan precipitates in the plates containing A549 and 
HeLa cells. Alternatively, plates containing either Jurkat-
pLVTHM or Jurkat-shBak were previously centrifuged for 15 
min at 2500 rpm. Thereafter, media was also eliminated and 
DMSO (100 µl per well) was added. The optical density was 
measured at 550 nm using a 96-well multiscanner autoreader 
(ELISA). The IC50 was calculated by nonlinear regression 
analysis using OriginPro8.
Thioredoxin inhibition assay. For determination of the 
thioredoxin reductase activity, A549 cells were incubated for 9 
h with our compound at different concentrations near IC50 
values. Cells were collected and washed with PBS and 150 μl 
buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris/HCl pH 7.6, 
10% v/v glycerol, 1 mM EDTA, 1 mM sodium orthovanadate, 
10 mM sodium pyrophosphate, 10 μg ml−1 leupeptin, 10 mM 
NaF, 1 mM sodium methylsulphonium) for 30 min at 0 °C, and 
centrifuged at 200 g for 10 min at 4 °C. The protein was 
quantified using the BCAprotein assay (Thermo Scientific) and 
80 μg was added in each assay. Kinetic studies were performed 
in a buffer containing 0.2 M NaCl, H-phosphate pH 7.4, 2 mM 
EDTA, 0.25 mM NADPH and 3 mM DTNB. The increase in the 
absorbance was measured at 412 nm for 5 min at 25 °C.
Intracellular peroxides (ROS) formation. The production of 
ROS (Reactive Oxygen Species) was assessed using the 
dichlorofluorescein (DCF) assay.45 Caco-2/TC7 cells were plated 
in 96-well plates at a density of 4000 cells perwell and 
incubated for 24 h under standard cell culture conditions. For 
treatment, 6 was added to cells within its IC50 concentration 
that of IC50 and incubated 24 h; mocktreated cells were just 
incubated with DMSO at the same concentration than treated 
cells. Then, cells were washed twice with PBS and 100 μL of 20 
mM DCFH-DA (dichloro-dihydro-fluoresceindiacetate) were 
added to each well. Cells were incubated 1 h at 37 °C and 
washed twice with PBS; finally, 100 μL of PBS were added and 
fluorescence was analyzed with DTX-880 (Beckman Counter). 
Excitation and emission settings were 485 and 535 nm, 
respectively. The intensity of fluorescence is considered as a 
reflection of total intracellular ROS.
Materials and Procedures
The starting materials [AuCl(tht)], [Au2Cl2(µ-dppe)] and 
[Au2Cl2(µ-dppp)] were prepared according to literature 
procedures.46 All other starting materials and solvents were 
purchased from commercial suppliers and used as received 
unless otherwise stated. 
Compound 1. [AuCl(PPh3)] (0.104 g, 0.211 mmol) was added to 
a solution of L1 (0.030 g, 0.211 mmol) in 30 ml of DCM. Then, 
an excess of Cs2CO3 was added and the mixture was stirred at 
r.t. for 24 h. Thereafter, the mixture was filtered through celite 
and the solvent was removed at high vacuum affording a white 
solid (0.063 g, 50%). 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.1 
Hz, 1H, CH(7)), 7.64-7.49 (m, 16H, CH(Ph), CH(2)), 7.36–7.33 
(m, 1H, CH(5)), 7.05 (dd, J = 8.0, 7.4 Hz, 1H, CH(6)), 6.76-6.74 
(m, 1H, CH(3)). 31P (162 MHz, CDCl3): δP 31.3; 13C NMR (101 
MHz, CDCl3) δC 144.6 (s, 1C, C(7a)), 138.8 (s, 1C, C(2)), 134.3 
(d, J = 13.7 Hz, 6C, C(orto-Ph)), 132.1 (d, J = 2.5 Hz, 3C, C(para-Ph), 
130.8 (s, 1C, C(3a)), 129.5 (d, J = 11.6 Hz, 6C, C(meta-Ph), 129.1 
(d, J = 59.9 Hz, 3C, C(ipso-Ph)), 123.8 (s, 1C, C(5)), 120.5 (s, 1C, 
CN), 119.3 (s, 1C, C(7)), 118.6 (s, 1C, C(6)), 101.6 (s, 1C, C(4)), 
100.0 (s, 1C, C(3)). MS (ESI+): m/z, 601.2 ([MH]+, 4.3%), 
calculated 601.1. IR, ʋ(solid, cm-1): 2213 (CN).
Compound 2. Compound 2 was synthesized following an 
analogous procedure to that of complex 1. Its experimental 
data agrees with that already reported somewhere else.19
Compound 3. This compound was prepared similarly to 1 using 
L3 instead of L1. The product was obtained as a maroon solid 
(0.072 g, 66% yield). 1H NMR (400 MHz, CDCl3) δ 7.53 (m, 15H, 
CH(Ph)), 7.13 (s, 1H, CH(4)), 7.00 (s, 1H, CH(6)), 2.51 (s, 3H, 
CH3(B)), 2.20 (s, 3H, CH3(A)). 31P (162 MHz, CDCl3): δP 32.1; 13C 
NMR (101 MHz, CDCl3) δC 189.7 (s, 1C, CO(3), 167.8 (s, 1C, 
CO(2)), 157.6 (s, 1C, C(7a)), 140.6 (s, 1C, C(6)), 134.2 (d, J = 13.6 
Hz, 6C, C(orto-Ph)), 132.0 (d, J = 2.1 Hz, 3C, C(paraPh)), 130.2 (s, 
1C, C(3a)), 129.3 (d, J = 11.7 Hz, 6C, C(meta-Ph), 128.9 (d, J = 61.6 
Hz, 3C, C(ipsoPh)), 122.7 (s, 1C, C(4)), 122.1 (s, 1C, C(5)), 120.9 
(s, 1C, C(7)), 20.4 (s, 2C, CH3(A)), 19.2 (s, 2C, CH3(B)). MS (ESI+): 
m/z, 634.1 ([MH]+, 24.8%), calculated 634.1. IR, ʋ(solid, cm-1): 
1719, 1679, 1615 (CO).
Compound 4. [Au2Cl2(µ-dppe)] (0.100 g, 0.115 mmol) was 
added to a solution of L1 (0.033 g, 0.232 mmol) in 30 ml of 
DCM. Then, an excess of Cs2CO3 was added and the mixture 
was stirred at r.t. for 24 h. Thereafter, the mixture was filtered 
through celite and the solvent was removed at high vacuum 
affording a white solid (0.052 g, 49%). 1H NMR (400 MHz, 
CDCl3) δ 7.78-7.62 (m, 10H, CH(7), CH(Ph)), 7.60-7.56 (m, 4H, 
CH(Ph)), 7.53-7.47 (m, 8H, CH(Ph)), 7.43 (d, J = 2.3 Hz, 2H, 
CH(2)), 7.35 (dd, J = 7.3, 0.8 Hz, 2H, CH(5)), 7.04-6.93 (m, 2H, 
CH(6)), 6.75 (d, J = 2.3 Hz, 2H, CH(3)), 2.85 (d, J = 2.2 Hz, 4H, 
CH(9)); 31P (162 MHz, CDCl3): δP 30.4; 13C NMR (101 MHz, 
CDCl3) δC 138.7 (s, 2C, C(2)), 133.3 (t, J = 6.7 Hz, 8C, C(orto-Ph)), 
133.0 (s, 4C, C(para-Ph)), 130.0 (t, J = 5.8 Hz, 8C, C(meta-Ph)), 
123.9 (s, 2C, C(5)), 120.4 (s, 2C, C(7a)), 119.0 (s, 2C, C(7)), 118. 
(s, 2C, C(6)), 101.8 (s, 2C, C(4)), 100.4 (s, 2C, C(3)). MS (ESI+): 
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m/z, 1074.2 ([MH]+, 0.7%), calculated 1074.2, 933.3 ([M – L1]+, 
8%), calculated 933.1. IR, ʋ(solid, cm-1): 2208 (CN).
Compound 5. [Au2Cl2(µ-dppp)] (0.093 g, 0.105 mmol) was 
added to a solution of L1 (0.030 g, 0.211 mmol) in 30 ml of 
DCM. Then, an excess of Cs2CO3 was added and the mixture 
was stirred at r.t. for 24 h. Thereafter, the mixture was filtered 
through celite and the solvent was removed at high vacuum 
affording a white solid (0.058 g, 50 %). 1H NMR (400 MHz, 
CDCl3) δ 7.70 (d, J = 8.1 Hz, 2H, CH(7)), 7.62-7.53 (m, 8H, 
CHmeta(Ph)), 7.51-7.44 (m, 4H, CHpara(Ph)), 7.40-7.29 (m, 6H, 
CHorto(Ph), CH(5, 2)), 6.99-6.82 (m, 2H, CH(6)), 6.68 (d, J = 2.5 
Hz, 2H, CH(3)), 2.91 (dt, J = 10.3, 7.0 Hz, 4H, CH(9)), 2.12-1.93 
(m, 2H, CH(10)). 31P (162 MHz, CDCl3): δP 23.4; 13C NMR (101 
MHz, CDCl3) δC 144.5 (s, 2C, C(7a)), 139.0 (s, 2C, C(2)), 133.2 
(d, J = 13.0 Hz, 8C, C(orto-Ph)), 132.5 (d, J = 2.3 Hz, 4C, C(para-Ph)), 
131.0 (s, 2C, C(3a)), 129.7 (d, J = 11.5 Hz, 8C, C(meta-Ph)), 128.2 
(d, J = 60.0 Hz, 4C, C(ipso-Ph)), 123.8 (s, 2C, C(5)), 121.1 (d, J = 
121.2 Hz, 2C, CN), 119.2 (s, 2C, C(7)), 118.7 (s, 2C, C(6)), 101.5 
(s, 2C, C(4)), 100.2 (s, 2C, C(3)), 27.9 (dd, J = 37.9, 10.6 Hz, 2C, 
C(A)), 19.9 (s, 1C, C(B)). MS (ESI+): m/z, 947.0 ([M – L1]+, 100%), 
calculated 947.1. IR, ʋ(solid, cm-1): 2208 (CN).
Compound 6. This compound was prepared similarly to 4 using 
L2 instead of L1. The product was obtained as an orange solid 
(0.104 g, 83% yield). 1H NMR (400 MHz, CDCl3) δ 7.80-7.73 (m, 
8H, CHortho(Ph)), 7.57-7.41 (m, 12H, CHpara, meta(Ph)), 7.20 (td, J 
= 7.7, 1.4 Hz, 2H, CH(6)), 7.05 (d, J = 7.3 Hz, 2H, CH(4)), 6.76 (d, 
J = 7.7 Hz, 2H, CH(7)), 6.68 (td, J = 7.5, 0.8 Hz, 2H, CH(5)), 2.92-
2.73 (m, 4H, CH2(A)). 31P (162 MHz, CDCl3): δP 26.6. 13C NMR 
(101 MHz, CDCl3) δC 189.3 (s, 2C, CO(3)), 166.7 (s, 2C, CO(2)), 
160.7 (s, 2C, C(7a)), 138.4 (s, 2C, C(6)), 133.5 (t, J = 6.7 Hz, 8C, 
C(orto-Ph)), 132.5 (s, 4C, C(para-Ph)), 129.9 (t, J = 5.8 Hz, 8C, 
C(meta-Ph)), 127.8 (dd, J = 66.8, 6.9 Hz, 4C, C(ipso-Ph)), 124.2 (s, 
2C, C(4)), 121.5 (s, 2C, C(5)), 119.8 (s, 2C, C(3a)), 113.9 (s, 2C, 
C(7)), 23.9 (d, J = 38.51 Hz, 2C, CH2(A)). MS (ESI+): m/z, 638.1 
([M – L2]+, 100%), calculated 638.1. IR, ʋ(solid, cm-1): 1726, 
1682, 1601 (CO).
Compound 7. This compound was prepared similarly to 5 using 
L2 instead of L1. The product was obtained as a maroon solid 
(0.066 g, 59% yield). 1H NMR (400 MHz, CDCl3) δ 7.80-7.63 (m, 
8H, CHortho(Ph)), 7.53-7.44 (m, 12H, CHmeta / para(Ph)), 7.28-7.18 
(m, 4H, CH(6, 4)), 6.80- 6.70 (m, 4H, CH(7, 5)), 2.92 (dt, J = 10.4, 
7.0 Hz, 4H, CH2(A)), 2.01 (ddd, J = 23.8, 16.6, 7.0 Hz, 2H, 
CH2(B)). 31P (162 MHz, CDCl3): δP 25.4. 13C NMR (101 MHz, 
CDCl3) 189.5 (s, 2C, CO(3)) 166.7 (s, 2C, CO(2)), 161.7 (s, 2C, 
C(7a)), 138.1 (s, 2C, C(6)), 133.5 (d, J = 13.0 Hz, 8C, C(orto-Ph)), 
132.4 (d, J = 2.4 Hz, 4C, C(para-Ph)), 129.7 (d, J = 11.6 Hz, 8C, 
C(meta-Ph)), 128.4 (d, J = 60.3 Hz, 4C, C(ipso-Ph)), 124.6 (s, 2C, 
C(4)), 121.5 (s, 2C, C(5)), 120.3 (s, 2C, C(3a)), 114.1 (s, 2C, C(7)), 
28.0 (dd, J = 37.6, 10.0 Hz, 2C, CH2(A)), 20.1 (s, 1C, CH2(B)). MS 
(ESI+): m/z, 952.1 ([M – L2]+, 100%), calculated 952.1. IR, 
ʋ(solid, cm-1): 1726, 1682, 1602 (CO).
Compound 8 This compound was prepared similarly to 4 using 
L3 instead of L1. The product was obtained as a red solid 
(0.108 g, 82% yield). 1H NMR (400 MHz, CDCl3) δ 7.84-7.72 (m, 
8H, CHortho(Ph)), 7.55-7.47 (m, 12H, CHmeta/para(Ph)), 6.84 (s, 2H, 
CH(6)), 6.76 (s, 2H, CH(4)), 2.83 (d, J = 7.2 Hz, 4H, CH2(C)), 2.61 
(s, 6H, CH3(B)), 2.41 (s, 6H, CH3(A)). 31P (162 MHz, CDCl3): δP 
27.4. 13C NMR (101 MHz, CDCl3) 189.8 (s, 2C, CO(3)), 167.4 (s, 
2C, CO(2)), 156.9 (s, 2C, C(7a)), 141.0 (s, 2C, C(6)), 133.5 (t, J = 
6.7 Hz, 8C, C(orto-Ph)), 132.4 (s, 4C, C(para-Ph)), 130.4 (s, 2C, 
C(3a)), 129.8 (t, J = 5.8 Hz,8C, C(meta-Ph)), 128.4 (d, J = 59.9 Hz, 
4C, C(ipso-Ph)), 122.3 (s, 2C, C(4)), 121.9 (s, 2C, C(5)), 120.6 (s, 
2C, C(7)), 24.3 (d, J = 40.0 Hz, 2C, CH2(C)), 20.5 (s, 2C, CH3(A)), 
19.1 (s, 2C, CH3(B)). MS (ESI+): m/z, 966.1 ([M – L3]+, 100%), 
calculated 966.1. IR, ʋ(solid, cm-1): 1730, 1669, 1616 (CO).
Compound 9. This compound was prepared similarly to 5 using 
L2 instead of L1. The product was obtained as a dark red solid 
(0.064 g, 65% yield). 1H NMR (400 MHz, CDCl3) δ 7.76-7.68 (m, 
8H, CHortho(Ph)), 7.52-7.41 (m, 12H, CHmeta/para(Ph)), 6.94 (s, 2H, 
CH(6)), 6.81 (s, 2H, CH(4)), 2.98-2.89 (m, 4H, CH2(C)), 2.29 (s, 
6H, CH3(B)), 2.16 (s, 6H, CH3(A)), 2.09-1.92 (m, 2H, CH2(D)). 31P 
(162 MHz, CDCl3): δP 25.0. 13C NMR (101 MHz, CDCl3) 189.7 (s, 
2C, CO(3)), 167.5 (s, 2C, CO(2)), 157.2 (s, 2C, C(7a)), 140.7 (s, 
2C, C(6)), 133.4 (d, J = 13.0 Hz, 8C, C(orto-Ph)), 132.1 (s, 4C, 
C(para-Ph)), 129.5 (d, J = 11.5 Hz, 8C, C(meta-Ph)), 128.8 (d, J = 
60.17 Hz, 4C, C(ipso-Ph)), 122.4 (s, 2C, C(4)), 122.0 (s, 2C, C(5)), 
120.6 (s, 2C, C(7)), 27.8 (d, J = 44.1 Hz, 2C, CH2(C)), 20.4 (s, 2C, 
CH3(A)), 20.3 (s, 1C, CH2(D)), 19.0 (s, 2C, CH3(B)). MS (ESI+): 
m/z, 980.1 ([M – L3]+, 100%), calculated 980.1. IR, ʋ(solid, cm-
1): 1722, 1678, 1615 (CO).
Conclusions
In summary, we have reported the synthesis of luminescent 
monometallic [AuLPPh3] (1-3) and bimetallic [Au2(-dppe)L2] 
(4, 6, 8) and [Au2(-dppp)L2] (5, 7, 9) complexes, where L is 
either 4-cyanoindole, isatin, or 5,7-dimethyl-isatin. Structural 
characterisation by X-ray diffraction showed the expected 
linear disposition around the gold metal centre as well as the 
predisposition to form intramolecular aurophilic interactions 
for those complexes containing dppe as bridge ligand. All 
complexes displayed a similar emission profile around 400 nm. 
Theoretical calculations revealed that the origin of the 
emission was dependent on the nature of the heterocycle. 
Thus, in the case of the indole derivatives a mixture of LLCT 
and LMCT seemed to be the source of the emission, whereas 
an IL (isatin based) and a LMCT transitions in the case of the 
isatin derivatives. Additionally, the lifetimes in the range of 
hundreds of nanoseconds suggests the fluorescence nature of 
the emissions. As result of these data, i.e. the high-energy 
excitation and emission as well as the short lifetimes, these 
complexes cannot be considered suitable for cell imaging 
purposes. In contrast, cell antiproliferative assays performed in 
lung cancer (A549), cervix cancer (HeLa), leukemia Jurkat-
pLVTHM and Jurkat-shBak cells showed a similar cytotoxic 
behaviour for the three families of complexes, being the 
bimetallic species at least twice as toxic as the monometallic, 
with IC50 values between 10.11 and 0.28 μM. Additional MTT 
assays performed to the free ligands L1-L3 and dppe and dppp 
ligands point towards the metal centre as the main responsible 
of such cytotoxicity. Initial studies on thioredoxin inhibition 
and reactive oxygen species suggest a different biological 
target than that of thioredoxin for these gold complexes. 
Although these are preliminary studies, the fact that the 
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synthesised complexes inhibit the cell proliferation of both, 
leukemia Jurkat-pLVTHM and Jurkat-shBak cells, cisplatin 
sensitive and resistant cells respectively, suggest the novel 
complexes as an alternative cisplatin drug for the treatment of 
this specific disease. 
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Graphical Abstract 
Bioactive and luminescent indole and isatin based gold(I) derivatives
Vanesa Fernández-Moreira,* Cynthia Val-Campillo, Isaura Ospino, Raquel P. Herrera, Isabel Marzo, 
Antonio Laguna and M. Concepción Gimeno*
Combination of bioactive indole and isatin derivatives with Au(I) affords highly cytotoxic 
metallic species even for cisplatin resistant leukemia cells (Jurkat-shBak).
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